more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.58 USD

+1.11 (0.55%)

Updated Nov 5, 2024 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Zacks News

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

by Zacks Equity Research Published on March 31,2020

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

pharmaceuticals

Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children

by Zacks Equity Research Published on March 31,2020

The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.

pharmaceuticals

Top Ranked Income Stocks to Buy for March 31st

by Zacks Equity Research Published on March 31,2020

Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 31st.

gold
retail

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

by Sejuti Banerjea Published on March 30,2020

The WHO's Solidarity testing project could be good news for the world.

medical

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - March 30, 2020

by Zacks Equity Research Published on March 30,2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia

by Zacks Equity Research Published on March 27,2020

The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.

pharmaceuticals

Will Rescue Deal Impact Last? 4 Coronavirus-Proof Dividend Picks

by Urmimala Biswas Published on March 27,2020

With the ongoing erratic movement of most stocks, it's a prudent idea for investors to go for dividend-paying stocks as a regular source of income.

Top Ranked Income Stocks to Buy for March 27th

by Zacks Equity Research Published on March 27,2020

Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 27th

AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia

by Zacks Equity Research Published on March 26,2020

The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.

Top Ranked Income Stocks to Buy for March 26th

by Zacks Equity Research Published on March 26,2020

Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 26th.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research Published on March 25,2020

AbbVie (ABBV) closed the most recent trading day at $67.91, moving +0.62% from the previous trading session.

ABBVPositive Net Change

Coronavirus Drug Development Race to Boost These 4 Stocks

by Zacks Equity Research Published on March 25,2020

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

by Zacks Equity Research Published on March 25,2020

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

biotechs

The Extreme Risks of Trading Your Own Retirement Assets - March 25, 2020

by Zacks Equity Research Published on March 25,2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.